enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First patients enrolled in surfactant plus detalimogene cohort Approximately 50% reduction in force to streamline operations and preserve cash to focus on BLA and precommercial activities […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.